Johnson & Johnson Analyst Forecasts: Strong Buy Ratings and Price Targets

Recent analysis provides new insights on $JNJ as Johnson Rice issues a ‘Buy’ rating.

Analyst Ratings for $JNJ

Multiple Wall Street analysts have recently provided outlooks on $JNJ. In the past few months, three firms have issued buy ratings, while no firms have issued sell ratings.

Recent analyst ratings include:

• Johnson Rice issued a “Buy” rating on 05/15/2025.
• Raymond James issued an “Outperform” rating on 04/16/2025.
• Citigroup issued a “Buy” rating on 01/22/2025.

Price Targets for $JNJ

Analysts have also set price targets for $JNJ. Over the past six months, two analysts have provided targets, resulting in a median target of $164.00.

Recent price targets include:

• Jayson Bedford from Raymond James set a target price of $162.00 on 04/14/2025.
• Vamil Divan from Guggenheim set a target price of $166.00 on 02/03/2025.

Congressional Trading of $JNJ Stock

In the last six months, members of Congress have traded $JNJ stock 26 times, with 19 purchases and 7 sales.

Here’s a breakdown of some recent trades by Congress members:

• Representative Marjorie Taylor Greene has traded 6 times, purchasing shares worth up to $90,000 on various dates.
• Representative Gilbert Ray Cisneros, Jr. traded 3 times, making one purchase worth up to $50,000 and two sales totaling up to $30,000.
• Representative Bruce Westerman made 2 trades, with one purchase and one sale each worth up to $15,000.
• Representative Robert Bresnahan sold shares worth up to $15,000.
• Representative George Whitesides sold shares worth up to $250,000.
• Representative Josh Gottheimer traded 7 times, making six purchases and one sale, totaling up to $90,000 and $15,000, respectively.
• Representative Jefferson Shreve purchased shares worth up to $100,000.
• Representative Lloyd Doggett made two purchases worth up to $30,000.
• Representative Kevin Hern sold shares worth up to $250,000.
• Representative Virginia Foxx purchased shares worth up to $15,000.

Insider Trading Activity for $JNJ

Insiders at $JNJ have engaged in trading on the open market four times in the past six months. This includes one purchase and three sales.

Details of recent insider transactions are as follows:

• Joseph J. Wolk (Exec VP, CFO) sold 13,015 shares for an estimated $2,002,878.
• Robert J. Decker (VP Corporate Controller) sold 6,999 shares for an estimated $1,160,994.
• Mark A. Weinberger purchased 1,000 shares for an estimated $147,220.
• Timothy Schmid (EVP, WW Chair, MedTech) sold 403 shares for an estimated $62,928.

Hedge Fund Activity Related to $JNJ

Recent quarters show that 1,832 institutional investors increased their holdings of $JNJ, while 2,070 reduced their positions.

Notable movements include:

• JPMorgan Chase & Co added 15,277,413 shares (+39.4%) in Q1 2025, valued at approximately $2,533,606,171.
• Price T Rowe Associates Inc removed 6,177,098 shares (-37.9%) in Q1 2025, valued at around $1,024,409,932.
• Robert Wood Johnson Foundation reduced their holdings by 6,167,294 shares (-71.0%) in Q1 2025, valued at approximately $1,022,784,036.
• Bank of New York Mellon Corp added 4,842,582 shares (+26.4%) in Q1 2025, valued at about $803,093,798.
• Legal & General Group PLC decreased their position by 4,603,436 shares (-19.9%) in Q4 2024, valued at an estimated $665,748,914.
• Janus Henderson Group PLC increased their holdings by 4,559,147 shares (+134.5%) in Q4 2024, valued at about $659,343,839.
• Lazard Asset Management LLC reduced their holdings by 3,705,273 shares (-85.3%) in Q4 2024, valued at an estimated $535,856,581.

This article is not financial advice. See Quiver Quantitative’s disclaimers for more information.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.